There are limitations to the sensitivity and specificity of conventional two-dimensional echocardiograms in making an accurate diagnosis in certain patient populations. This led to the development of specific contrast-enhancing agents with the following characteristics: small enough to cross the pulmonary capillary bed, remain stable throughout the length of the procedure, do not dissolve in blood, and rapidly cleared from the body with low toxicity.
INTRODUCTION
Contrast echocardiography is not widely ordered as a diagnostic imaging modality, probably due to poor understanding, even among cardiologists, of its clinical application and safety profile. This article serves to demystify and clarify conditions in which adding a contrast agent to routine echocardiography can result in a very powerful diagnostic tool. Contrast echocardiography is simply an imaging technique for enhancing the endocardium and blood border wall. Agitated saline microbubbles were previously used to examine the right heart (mainly the right atrium) and identify intracardiac shunts. These air microbubbles are shortlasting and could not even reach the left heart, as they would have diffused into the lungs while passing through the pulmonary circulation.
ULTRASOUND ENHANCING AGENTS
In order to evaluate the left heart chambers, the contrast agent must be small and stable so as to remain intact after crossing the pulmonary circulation to reach the left heart after being administered intravenously. The use of ultrasound enhancing agents (UEAs) consisting of inert gases (perfluorocarbons and sulfur hexafluoride), which have lower solubility and diffusivity than air, encapsulated with lipid or protein shells markedly increases the lifespan of the contrast agent after injection. These modifications have resulted in more stable microbubbles (< 6 µm) that can traverse the pulmonary or systemic microcirculations without getting lysed. (1) Table I shows the commons UEAs that have been clinically approved for use. They demonstrated that Definity was well tolerated in routine clinical practice in patients with a high prevalence of cardiopulmonary disease. (5) On a similar note, Main et al reported in 2013 that at a clinically relevant dose of 0.5 mL Optison, pulmonary artery systolic pressure or pulmonary vascular resistance did not change after intravenous administration. (6) These two studies reinforced the safety of UEAs for cardiac indications.
Since then, numerous studies have demonstrated the safety of UEAs in various clinical settings (e.g. emergency and intensive care departments) as well as in the paediatric population. UEAs are also safe to use in patients undergoing stress echocardiography and in those suspected of having pulmonary hypertension and intracardiac shunts. In 2008, the FDA downgraded the contraindications listed in the black box to warnings. In 2011, it had removed the mandatory 30 minutes of monitoring after UEA administration in patients with pulmonary hypertension or unstable cardiopulmonary conditions. In late 2016 and early 2017, the FDA further removed the contraindication for administration of Optison, Lumason/SonoVue, and Definity in patients with intracardiac shunts. In fact, the American Society of Echocardiography (ASE) 2018 guideline recommends routine use of contrast agents in evaluating patients with patent foramen ovale and small right-to-left shunts. (7, 8) Contrast agents can also be used in LV assist devices and extracorporeal membrane oxygenators (ECMOs), although care must be taken to avoid ECMO circuit shutdowns due to bubble-sensing safety systems. (9) As of August 2017, the only contraindication was intraarterial injection; and for SonoVue and Definity, known hypersensitivity to sulfur hexafluoride and perflutren, respectively. In summary, despite initial FDA contraindications to the contrary, there is substantial evidence to show that echocardiographic contrast agents are not only safe in critically ill patients but also that important diagnostic data can potentially be derived from these studies.
THE CHANGI GENERAL HOSPITAL EXPERIENCE
At Changi General Hospital (CGH), we started using Definity in 2008 and later switched to SonoVue in 2012 due to a cost issue. In 2012-2017, there were a total of 395 contrast echocardiographic studies performed with SonoVue, including both transthoracic and stress echocardiograms. For Definity, there were two cases of non-specific back pain. In the one case of anaphylactic shock with SonoVue, the patient responded promptly to fluid resuscitation with no further clinical sequel. Currently, we use UEA in about 1% of our stress and regular echocardiograms.
CLINICAL UTILITY OF CONTRAST ECHOCARDIOGRAPHY
The main indication for contrast echocardiography is for assessment of LV ejection fraction and regional wall motion abnormalities (RWMA). (7) (8) (9) (10) (11) (12) which is characteristic of apical hypertrophic cardiomyopathy, can be better delineated with UEA. (13) It also allows the echocardiographer to measure the myocardial thickness more accurately with confidence. (b) For LV noncompaction, the noncompacted layer can be differentiated more easily against the compacted myocardium by enhancing the LV cavity with UEA. (14) The ASE recommends a noncompacted to compacted ratio of > 2:1 when using contrast to make the diagnosis of LV noncompaction. (c) Weinsaft et al (15) have demonstrated the superiority of contrast over noncontrast echocardiography for the detection of LV, especially apical thrombi, with improved sensitivity (61% vs. 33%, p < 0.05) and accuracy (92% vs. 82%, p < 0.01). As such, the ASE recommends that UEA be used in patients with severely impaired LV systolic function and in whom the apex is not well visualised, to assess Page 6 of 10 for suspicious thrombi. (d) LV apical aneurysm is characterised by dilatation of thin and scarred apical myocardium. The use of UEA helps to delineate the aneurysm and even uncover concomitant LV apical thrombus, especially when the apex is not well visualised despite using multiplanar imaging technique on noncontrast echocardiography. (e) LV pseudoaneurysm, free wall rupture and ventricular septal defects are life-threatening complications that can develop in patients following myocardial infarction. (16) However, such patients, more often than not, are intubated due to acute pulmonary oedema from cardiogenic shock and thus, they will have suboptimal echocardiography windows due to anatomy and supine positioning. Contrast echocardiography can delineate abnormal anatomical structures more clearly and document the presence or absence of extracardiac extravasation of contrast agent in cases of suspected ventricular free wall rupture. 
COST-EFFECTIVENESS OF ULTRASOUND ENHANCING AGENTS
Studies (17) (18) (19) (20) have shown that contrast echocardiography helps to save healthcare costs through, first, reducing costlier or more invasive testing downstream in patients with an initially non-diagnostic echocardiogram, as contrast echocardiography can clearly demonstrate the diagnosis. In short, contrast echocardiogram has higher sensitivity and specificity for certain cardiac conditions and should be applied when clinically indicated.
Second, laboratory efficiency improves due to the shorter scanning time using contrast echocardiography in patients with poor echo windows. The echocardiographers can spend less unproductive time searching for optimal echocardiography images.
CONCLUSION
This article aims to improve practising doctors' knowledge of the indications, risks and benefits of contrast echocardiography. The future potential applications of UEAs in gene and drug delivery are beyond the scope of this article. Contrast echocardiography should be considered on a case-by-case basis depending on the clinical indication. As we have demonstrated, it is a powerful diagnostic tool that is readily available to complement conventional two-dimensional echocardiography.
